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DETECTION OF Mycobacterium leprae DNA FOR 36kDa PROTEIN IN URINE FROM LEPROSY
PATIENTS: A PRELIMINARY REPORT
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SUMMARY
We have searched for Mycobacterium leprae DNA for 36kDa protein in urine using a M. leprae specific PCR technique. A limited
number of 16 patients (of which 11 belonged to lepromatous leprosy and five to tuberculoid leprosy) and eight healthy individuals
were included for the present study. The number of urine samples positive by PCR were 36.4% (4/11) in lepromatous patients and
40% (2/5) in tuberculoid patients. None of the samples from healthy individuals was positive. To our knowledge, the results indicate,
for the first time, the presence of M. leprae DNA in urine from leprosy patients. Another important finding obtained out of the study
is that amongst treated patients 66.6% (4/6) were positive whereas amongst untreated only 20% (2/10) were positive. From the
present indicative data it appears that treatment improves the PCR results with urine as a sample. Thus, the approach could prove to
be useful for monitoring the treatment response of individual patients and needs to be further evaluated with a large number of
patients.
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Leprosy is a chronic infectious disease caused by Mycobacterium
leprae. The disease manifests in various forms resulting in a spectrum8.
At one pole of the spectrum lies tuberculoid leprosy (TT) while at the
other one lies lepromatous leprosy (LL). Between these two polar types
various borderline forms (i.e. BT-borderline tuberculoid, BB-mid-
borderline, BL-borderline lepromatous leprosy) have been described. In
tuberculoid leprosy there is a localized skin and/or nerve lesion(s), with
a low bacterial load and strong cell mediated immunity. In contrast,
lepromatous leprosy has generalized lesions with a high bacterial load
and strong humoral immunity. Immunological examination of urine from
leprosy patients has shown that samples from a proportion of leprosy
patients are positive for antigens and antibodies in the urine4,5,6. Though,
there are reports documenting mycobacterial DNA in urine from patients
suffering from infectious diseases7,10, to our knowledge, there is hardly
any information, demonstrating M. leprae DNA in urine from leprosy
patients. With skin biopsies from leprosy patients a specific PCR for
detection of DNA for 36kDa antigen has already been published1,2 in the
literature. In this pilot study, we have made an attempt to detect M. leprae
DNA for 36kDa protein in urine from leprosy patients.
Sixteen active leprosy patients (who attended the out patient
department at Central JALMA Institute for leprosy, Agra) and eight
healthy individuals were included for the study. Patients were diagnosed
using clinical criteria and classified according to RIDLEY & JOPLING8
scale. None of the patients had any symptom indicating the defective
renal function. Of the 16 patients, six were on anti leprosy treatment.
Various relevant clinical features have been depicted in Table 1.
After obtaining the informed consent from all the individuals, they
were requested to produce urine. Ten ml of the urine sample was
centrifuged at 12,074 g for 20 min at 4 oC. The supernatant was discarded
and the pellet was suspended in 500 µl of 10 mM Tris-HCl supplemented
with 1 mM ethylene diamine tetra-acetic acid (TE, pH 8.0). If needed,
samples were stored at -20 oC till they were used.
The suspension of urine sediment (430 µl) in TE was boiled for 10
minutes. It was then followed by sudden cooling and treatment with 50
µl lysozyme (20 mg/ml) for two hrs at 37 oC. Next, 5 µl of proteinase-K
(10 mg/ml) and 56 µl of 10% sodium dodecyl sulphate (SDS) were mixed
and incubated for one hour at 65 oC. Then, 80 µl of 5 M sodium chloride
(NaCl) and 64 µl cetyl tri-methylammonium bromide (CTAB; 20mg/
ml) were added to the mixture and incubated for 30 min at 65 oC. The
suspension thus obtained was treated with equal volume of chloroform-
iso-alcohol (1:24) solution, vortexed and centrifuged at 12,074 g for
five minutes. Supernatant was mixed with iso-propanol (0.6 times by
volume) in a separate tube. The contents of the tube were kept at -20 oC
overnight. Later on, the tube was centrifuged at 12,074 g for 15 min,
sediment in the tube was mixed after discarding the supernatant. Seventy
percent ethanol (150 µl) was then added to the mixture and the tube was
centrifuged for 7 minutes at 12,074 g. Finally, after drying the ethanol
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from the sample, 20 µl of TE buffer was added to the contents in the tube
and preserved at -20 oC till use. While performing this procedure all
precautions were taken to prevent cross contamination.
DNA extracted from samples were subjected to PCR following the
methods, with slight modification, described previously by
HARTSKEERL et al.2 and DE WIT et al.1 where the target for
amplification was 530 bp sequence on the gene encoding the 36kDa
antigen. The method included both, positive and negative controls. The
denaturation, annealing and extension steps were carried out at 94 oC
for two minutes, at 60 oC for two minutes and at 72 oC for three minutes
respectively. The amplicon obtained out of this procedure was analyzed
by agarose gel electorophoresis incorporated with 0.05 µl/ml of ethidium
bromide (0.5 mg/ml). On completion of the run the separated PCR
products were transferred to positively charged nylon membrane. The
transferred products were then probed with a digoxigenin labeled 530
bp fragment specific for DNA encoding for 36kDa antigen. All steps
including labeling of the probe, hybridization and detection employing
anti-digoxigenin antibody conjugated with alkaline phosphatase using
the substrate 5-bromo-4-chloro-3-indolyl phosphate and nitroblue
tetrazolium salt were performed as described by the manufacturer (Roche
Diagnostics, Mannheim, Germany). A specimen was considered positive
when a 530 bp band was revealed by both agarose gel electrophoresis
and subsequent hybridization.
The overall positivity rate (Table 2) with samples from leprosy
patients was 37.5% (6/16). None of the healthy controls was detected to
be positive. The group-wise positivity was 36.4% (4/11) with samples
from lepromatous patients and 40 percent (2/5) with samples from
borderline tuberculoid patients. In BT group of patients the cell mediated
immune response is known to be comparatively better than LL/BL type
of patients8. Probably, there may be continuous damage (at slow rate) of
M. leprae in BT patients resulting in more DNA release in the blood and
thereby more excretion in the urine leading to better positivity, though
insignificant, when compared to BL/LL patients. On the other hand,
with LL/BL patients the situation is reverse. Further, no association
between PCR status and clinical features including bacterial indices were
found. To conclude, detecting urinary DNA for 36kDa protein does not
appear to be a helpful tool for diagnosis of M. leprae infection.
In leprosy, efforts have been made in the past to demonstrate M.
leprae DNA in a variety of clinical samples such as skin, lymph, blood,
nasal secretions, hair bulbs and fresh biopsy9. To our knowledge, present
is the first report regarding demonstration of M. leprae DNA in urine
from leprosy patients. The appearance of M. leprae DNA in urine from
leprosy patients does not seem to be surprising as prevalence of antigens
and antibodies in urine from leprosy patients is already known4,5,6.
However, mechanism of getting DNA and even antigen and antibody is
not known as yet.
One interesting observation obtained out of the present study is that
amongst treated patients 66.7% (4/6) were positive whereas only 20%
(2/10) samples were positive from untreated group. Surprisingly, all the
patients having taken three or more than three months treatment were
positive by PCR. This indicative data points out that probably treatment
Table 1
Details of patients analyzed by PCR
Patient Disease duration Treatment duration Bacterial Index Type of disease PCR result
(Months) (Months) (BI)
1 6 Untreated 0 BT +
2 12 Untreated 0 BT -
3 1.5 Untreated 3 LL -
4 36 Untreated 5 LL -
5 24 5 4 LL +
6 24 Untreated 3 BL -
7 72 1.5 5 LL -
8 3 3 4 LL +
9 18 4 3 BL +
10 12 2 3 LL -
11 36 Untreated 3.5 LL -
12 18 Untreated 4 LL +
13 6 6 0 BT +
14 36 Untreated 0 BL -
15 12 Untreated 0 BT -
16 3 Untreated 0 BT -
Table 2
Performance of PCR for detection of M. leprae DNA in urine
Leprosy status Positive Negative Positivity (%)
Lepromatous 4/11 7/11 36.4
Tuberculoid 2/5 3/5 40
All 6/16 10/16 37.5
Healthy 0/8 8/8 0
Untreated 2/10 8/10 20
Treated 4/6 2/6 66.7
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affects the PCR results by enhancing the release of DNA in the urine. It
is known that due to treatment M. leprae is damaged and then eliminated
from the host tissues3. During this process, various bacterial components
including bacterial DNA might be released in the host tissues and DNA
thus released might get way in the urine. Hence, detecting DNA in urine
appears to be worthwhile to explore further on large number of samples
for establishing its utility in monitoring the response to chemotherapy
in leprosy patients.
RESUMO
Detecção do DNA do Mycobacterium leprae para proteína 36 kDa
na urina de pacientes com hanseníase: relato preliminar
Pesquisamos o DNA do Mycobacterium leprae para proteína 36 kDa
na urina usando a técnica do PCR específica para M. leprae. Um número
limitado de 16 pacientes (dos quais 11 tinham hanseníase multibacilar e
cinco hanseníase paucibacilar) e oito indivíduos saudáveis foram
incluídos neste estudo. O número de amostras de urina positivas pelo
PCR foi de 36,4% (4/11) em pacientes com hanseníase multibacilar e
40% (2/5) em pacientes com hanseníase paucibacilar. Nenhuma das
amostras de indivíduos saudáveis foi positiva. Até onde chega o nosso
conhecimento, os resultados indicam, pela primeira vez, a presença de
DNA do M. leprae na urina de pacientes com hanseníase. Outro fato
importante obtido através do exame é que entre os pacientes tratados
66.6% (4/6) eram positivos enquanto entre os não tratados somente 20%
(2/10) foram positivos. Pelos presentes dados indicativos parece que o
tratamento melhora os resultados do PCR em amostra de urina. Assim,
o acesso a estes dados prova ser útil no monitoramento da resposta ao
tratamento de pacientes individuais e precisa ser melhor avaliado com
um grande número de pacientes.
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